Peptides Similar to Cotadutide (MEDI0382)
Compare Cotadutide (MEDI0382) with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Tirzepatide: High - Both are dual incretin receptor agonists for metabolic disease, though they target different receptor pairs
- •Mazdutide: Very high - Both are GLP-1/glucagon dual agonists designed for metabolic disease including NASH
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Cotadutide (MEDI0382) (current) | - | - |
| Tirzepatide | High - Both are dual incretin receptor agonists for metabolic disease, though they target different receptor pairs | Tirzepatide is a GLP-1/GIP dual agonist while cotadutide was a GLP-1/glucagon dual agonist. Tirzepatide is weekly and FDA-approved; cotadutide was daily and discontinued. Different secondary receptor targets produce distinct metabolic effects. |
| Mazdutide | Very high - Both are GLP-1/glucagon dual agonists designed for metabolic disease including NASH | Mazdutide is a weekly GLP-1/glucagon dual agonist developed by Innovent Biologics/Eli Lilly, while cotadutide was a daily formulation by AstraZeneca. Mazdutide has progressed further in development and uses different structural modifications for half-life extension. |
| Semaglutide | Moderate - Both target GLP-1 receptors for metabolic disease, but semaglutide is a pure GLP-1 agonist while cotadutide adds glucagon receptor agonism | Semaglutide is a selective GLP-1 receptor agonist with weekly dosing and multiple FDA approvals. Cotadutide had dual GLP-1/glucagon agonism with daily dosing. Semaglutide achieves greater weight loss but lacks glucagon-mediated hepatic effects. |
TirzepatideHigh - Both are dual incretin receptor agonists for metabolic disease, though they target different receptor pairs
Differences
Tirzepatide is a GLP-1/GIP dual agonist while cotadutide was a GLP-1/glucagon dual agonist. Tirzepatide is weekly and FDA-approved; cotadutide was daily and discontinued. Different secondary receptor targets produce distinct metabolic effects.
Advantages
Tirzepatide is FDA-approved with proven efficacy for T2D and obesity (SURPASS and SURMOUNT programs), weekly dosing, dramatic weight loss (-22.5% in SURMOUNT-1), and robust commercial availability
Disadvantages
Tirzepatide lacks the glucagon-mediated hepatic benefits that were cotadutide's key differentiator; GIP agonism may have different metabolic effects than glucagon agonism on liver fat
MazdutideVery high - Both are GLP-1/glucagon dual agonists designed for metabolic disease including NASH
Differences
Mazdutide is a weekly GLP-1/glucagon dual agonist developed by Innovent Biologics/Eli Lilly, while cotadutide was a daily formulation by AstraZeneca. Mazdutide has progressed further in development and uses different structural modifications for half-life extension.
Advantages
Mazdutide has weekly dosing, more advanced clinical program (phase 3), and is being developed as a successor approach in the GLP-1/glucagon agonist space
Disadvantages
Limited data compared to cotadutide in Western populations; still investigational
SemaglutideModerate - Both target GLP-1 receptors for metabolic disease, but semaglutide is a pure GLP-1 agonist while cotadutide adds glucagon receptor agonism
Differences
Semaglutide is a selective GLP-1 receptor agonist with weekly dosing and multiple FDA approvals. Cotadutide had dual GLP-1/glucagon agonism with daily dosing. Semaglutide achieves greater weight loss but lacks glucagon-mediated hepatic effects.
Advantages
Semaglutide is FDA-approved with extensive clinical evidence, weekly and oral formulations, proven cardiovascular benefit, and market- leading efficacy for weight loss
Disadvantages
Semaglutide lacks glucagon receptor agonism that may provide additional hepatic fat reduction benefit; does not address the specific dual agonist metabolic hypothesis
Peptides Related to Cotadutide#
Cotadutide (MEDI0382) occupied a unique position in the metabolic peptide landscape as a GLP-1/glucagon dual agonist. This class of dual agonists represents a distinct therapeutic approach from both selective GLP-1 agonists and GLP-1/GIP dual agonists.
Tirzepatide (Mounjaro / Zepbound)#
Tirzepatide is the most commercially successful dual incretin agonist, but it targets a different receptor pair (GLP-1/GIP) than cotadutide (GLP-1/glucagon). Both approaches aim to improve upon selective GLP-1 agonism, but through different mechanisms. The GIP component of tirzepatide primarily enhances insulin secretion and may improve insulin sensitivity, while the glucagon component of cotadutide was designed primarily for hepatic metabolic benefits including enhanced fat oxidation and reduced liver fat.
Mazdutide#
Mazdutide is the closest molecular comparator to cotadutide, as both are GLP-1/glucagon dual agonists. However, mazdutide achieves weekly dosing through different structural modifications and has progressed further in clinical development. Mazdutide's continued advancement suggests that the GLP-1/glucagon dual agonist concept remains viable, with cotadutide's discontinuation driven by its daily dosing limitation rather than the mechanism.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide serves as the reference standard for GLP-1 receptor agonist therapy. In cotadutide's phase 2b trial, liraglutide (not semaglutide) was used as the active comparator. Cotadutide's unique differentiator was the hepatic biomarker improvements driven by glucagon receptor agonism, which were not observed with the GLP-1-only comparator. Whether these biomarker improvements would translate to meaningful clinical outcomes in NASH was never tested.
Summary Comparison#
| Feature | Cotadutide | Tirzepatide | Mazdutide | Semaglutide |
|---|---|---|---|---|
| Receptor targets | GLP-1R + GCGR | GLP-1R + GIPR | GLP-1R + GCGR | GLP-1R |
| Dosing | Daily SC | Weekly SC | Weekly SC | Weekly SC / Daily oral |
| Hepatic effects | Significant | Moderate | Expected | Moderate |
| Weight loss | Moderate | Very high | High | High |
| Status | Discontinued | Approved | Phase 3 | Approved |
Comparison Context#
Cotadutide (MEDI0382) belongs to the Metabolic category of research peptides. Comparing Cotadutide (MEDI0382) with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Cotadutide (MEDI0382) in mechanism, indication, or therapeutic category:
Cotadutide (MEDI0382) vs Tirzepatide#
Similarity: High - Both are dual incretin receptor agonists for metabolic disease, though they target different receptor pairs
Key Differences: Tirzepatide is a GLP-1/GIP dual agonist while cotadutide was a GLP-1/glucagon dual agonist. Tirzepatide is weekly and FDA-approved; cotadutide was daily and discontinued. Different secondary receptor targets produce distinct metabolic effects.
Advantages of Tirzepatide: Tirzepatide is FDA-approved with proven efficacy for T2D and obesity (SURPASS and SURMOUNT programs), weekly dosing, dramatic weight loss (-22.5% in SURMOUNT-1), and robust commercial availability
Disadvantages of Tirzepatide: Tirzepatide lacks the glucagon-mediated hepatic benefits that were cotadutide's key differentiator; GIP agonism may have different metabolic effects than glucagon agonism on liver fat
Researchers choosing between Cotadutide (MEDI0382) and Tirzepatide should consider the development stage, available evidence, and specific research objectives when making their selection.
Cotadutide (MEDI0382) vs Mazdutide#
Similarity: Very high - Both are GLP-1/glucagon dual agonists designed for metabolic disease including NASH
Key Differences: Mazdutide is a weekly GLP-1/glucagon dual agonist developed by Innovent Biologics/Eli Lilly, while cotadutide was a daily formulation by AstraZeneca. Mazdutide has progressed further in development and uses different structural modifications for half-life extension.
Advantages of Mazdutide: Mazdutide has weekly dosing, more advanced clinical program (phase 3), and is being developed as a successor approach in the GLP-1/glucagon agonist space
Disadvantages of Mazdutide: Limited data compared to cotadutide in Western populations; still investigational
Researchers choosing between Cotadutide (MEDI0382) and Mazdutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Cotadutide (MEDI0382) vs Semaglutide#
Similarity: Moderate - Both target GLP-1 receptors for metabolic disease, but semaglutide is a pure GLP-1 agonist while cotadutide adds glucagon receptor agonism
Key Differences: Semaglutide is a selective GLP-1 receptor agonist with weekly dosing and multiple FDA approvals. Cotadutide had dual GLP-1/glucagon agonism with daily dosing. Semaglutide achieves greater weight loss but lacks glucagon-mediated hepatic effects.
Advantages of Semaglutide: Semaglutide is FDA-approved with extensive clinical evidence, weekly and oral formulations, proven cardiovascular benefit, and market- leading efficacy for weight loss
Disadvantages of Semaglutide: Semaglutide lacks glucagon receptor agonism that may provide additional hepatic fat reduction benefit; does not address the specific dual agonist metabolic hypothesis
Researchers choosing between Cotadutide (MEDI0382) and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Cotadutide (MEDI0382)
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer